Abstract：
Central nervous system tumors are abnormal proliferations of neuronal cells within the brain and spinal cord. They can be primary or secondary and place a heavy financial, psychological, and physical burden on individuals. The highly selective blood-brain barrier, which only permits specific molecules to flow into the brain parenchyma, inhibits the efficacy of pharmacological medicines. Treatment options include surgery, chemoradiotherapy, and targeted therapy. Despite advances in therapy over the past few decades, the overall morbidity and mortality rates are still high, emphasizing the need for improved therapeutic choices to improve survival and quality of life further. Nano pharmaceuticals have demonstrated encouraging outcomes in in vivo trials using microscopic particles to enhance bioavailability and selectivity. The most successful clinical results to date have been achieved by liposomes, extracellular vesicles, and biomimetic nanoparticles; nevertheless, clinical trials are required to confirm their safety, efficacy, affordability, longterm impact, and success in patients from various demographics. Nano pharmaceuticals have the potential to change the paradigm of therapy for brain tumors, allowing better outcomes as primary and adjunctive therapy.
摘要：
中枢神经系统肿瘤是脑和脊髓内神经元细胞的异常增殖。它们可以是主要的，也可以是次要的，并放置沉重的财务，心理,和个人的身体负担。高选择性血脑屏障,只允许特定分子流入脑实质，抑制药物的功效。治疗方案包括手术,放化疗,和靶向治疗。尽管治疗在过去几十年取得了进展，总体发病率和死亡率仍然很高，强调需要改进治疗选择，以进一步提高生存率和生活质量。纳米药物在使用微观粒子增强生物利用度和选择性的体内试验中已经证明了令人鼓舞的结果。迄今为止最成功的临床结果是脂质体，细胞外囊泡，和仿生纳米粒子；尽管如此，需要进行临床试验以确认其安全性，功效,负担能力，长期影响，以及来自各种人口统计学的患者的成功。纳米药物有可能改变脑肿瘤的治疗模式，允许更好的结果作为主要和辅助治疗。
